Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

A COVID-19 Prophylaxis? Lower incidence associated with prophylactic administration of Ivermectin

Hellwig et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106248
Nov 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Case 78% Improvement Relative Risk Case (b) 80% Ivermectin for COVID-19  Hellwig et al.  Prophylaxis Does ivermectin reduce COVID-19 infections? Ecological study in multiple countries Fewer cases with ivermectin (p=0.017) c19ivm.org Hellwig et al., Int. J. Antimicrobial .., Nov 2020 Favorsivermectin Favorscontrol 0 0.5 1 1.5 2+
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
 
*, now with p < 0.00000000001 from 104 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19ivm.org
Analysis of COVID-19 cases vs. widespread prophylactic use of ivermectin for parasitic infections showing significantly lower incidence of COVID-19 cases.
This is the 22nd of 104 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 1 sextillion).
51 studies are RCTs, which show efficacy with p=0.00000015.
This study is excluded in the after exclusion results of meta analysis: not a typical trial, analysis of African countries that used or did not use ivermectin prophylaxis for parasitic infections.
risk of case, 78.0% lower, RR 0.22, p < 0.02, African countries, PCTI vs. no PCT, relative cases per capita.
risk of case, 80.0% lower, RR 0.20, p < 0.001, worldwide, PCTI vs. no PCT, relative cases per capita.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Hellwig et al., 28 Nov 2020, retrospective, ecological study, multiple countries, peer-reviewed, 2 authors, dosage 200μg/kg, dose varied, typically 150-200μg/kg.
This PaperIvermectinAll
A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin
Martin D Hellwig, Anabela Maia
International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106248
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre -including this research content -immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Supplementary materials Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.ijantimicag.2020. 106248 .
References
Al-Tawfiq, Al-Homoud, Memish, Remdesivir as a possible therapeutic option for the COVID-19, Travel Med Infect Dis, doi:10.1016/j.tmaid.2020.101615
Allcott, Boxell, Conway, Gentzkow, Thaler et al., Polarization and public health: partisan differences in social distancing during the coronavirus pandemic, National Bureau of Economic Research, doi:10.3386/w26946
Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res, doi:10.1016/j.antiviral.2020.104787
Cohen, Vaccine designers take first shots at COVID-19, Science, doi:10.1126/science.368.6486.14
Colson, Rolain, Lagier, Brouqui, Raoult, Chloroquine and hydroxychloroquine as available weapons to fight COVID-19, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105932
Fink, Porras, Pharmacokinetics of ivermectin in animals and humans, doi:10.1007/978-1-4612-3626-9_7
Greene, Taylor, Cupp, Murphy, White et al., Comparison of ivermectin and diethylcarbamazine in the treatment of onchocerciasis, N Engl J Med, doi:10.1056/NEJM198507183130301
Heidary, Gharebaghi, a systematic review from antiviral effects to COVID-19 complementary regimen, J Antibiot, doi:10.1038/s41429-020-0336-z
Munster, Koopmans, Van Doremalen, Van Riel, De, A novel coronavirus emerging in China-key questions for impact assessment, N Engl J Med, doi:10.1056/NEJMp2000929
Muñoz, Ballester, Antonijoan, Gich, Rodríguez et al., Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers, PLoS Negl Trop Dis, doi:10.1371/journal.pntd.0006020
Rajter, Sherman, Fatteh, Vogel, Sacks et al., ICON (Ivermectin in COvid Nineteen) Study: use of ivermectin is associated with lower mortality in hospitalized patients with COVID-19, doi:10.2139/ssrn.3631261
Richard-Lenoble, Chandenier, Gaxotte, Ivermectin and filariasis, Fundam Clin Pharmacol, doi:10.1046/j.1472-8206.2003.00170.x
Scheim, Ivermectin for COVID-19 treatment: clinical response at quasithreshold doses via hypothesized alleviation of CD147-mediated vascular occlusion, doi:10.2139/ssrn.3636557
Schmith, Zhou, Lohmer, The approved dose of ivermectin alone is not the ideal dose for the treatment of COVID-19, Clin Pharmacol Ther, doi:10.1002/cpt.1889
Singer, The COVID-19 pandemic: growth patterns, power law scaling, and saturation, Phys Biol, doi:10.1088/1478-3975/ab9bf5
Van Norman Gadrugs, Devices, and the FDA: Part 1: an overview of approval processes for drugs, JACC Basic Transl Sci, doi:10.1016/j.jacbts.2016.03.002
Wang, Horby, Hayden, Gao, A novel coronavirus outbreak of global health concern, Lancet, doi:10.1016/S0140-6736(20)30185-9
Zhou, Hou, Shen, Huang, Martin et al., Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2, Cell Discov, doi:10.1038/s41421-020-0153-3
{ 'indexed': {'date-parts': [[2024, 3, 28]], 'date-time': '2024-03-28T16:36:50Z', 'timestamp': 1711643810150}, 'reference-count': 21, 'publisher': 'Elsevier BV', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2021, 1, 1]], 'date-time': '2021-01-01T00:00:00Z', 'timestamp': 1609459200000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}], 'content-domain': { 'domain': [ 'clinicalkey.jp', 'clinicalkey.com', 'clinicalkey.es', 'clinicalkey.com.au', 'clinicalkey.fr', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2021, 1]]}, 'DOI': '10.1016/j.ijantimicag.2020.106248', 'type': 'journal-article', 'created': { 'date-parts': [[2020, 11, 28]], 'date-time': '2020-11-28T16:15:37Z', 'timestamp': 1606580137000}, 'page': '106248', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 40, 'title': 'A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ' 'ivermectin', 'prefix': '10.1016', 'volume': '57', 'author': [ { 'ORCID': 'http://orcid.org/0000-0001-8841-7545', 'authenticated-orcid': False, 'given': 'Martin D.', 'family': 'Hellwig', 'sequence': 'first', 'affiliation': []}, {'given': 'Anabela', 'family': 'Maia', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.ijantimicag.2020.106248_bib0001', 'doi-asserted-by': 'crossref', 'first-page': '470', 'DOI': '10.1016/S0140-6736(20)30185-9', 'article-title': 'A novel coronavirus outbreak of global health concern', 'volume': '395', 'author': 'Wang', 'year': '2020', 'journal-title': 'Lancet'}, { 'key': '10.1016/j.ijantimicag.2020.106248_bib0002', 'doi-asserted-by': 'crossref', 'first-page': '692', 'DOI': '10.1056/NEJMp2000929', 'article-title': 'A novel coronavirus emerging in China—key questions for impact ' 'assessment', 'volume': '382', 'author': 'Munster', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.ijantimicag.2020.106248_bib0003', 'series-title': 'COVID-19 coronavirus pandemic', 'year': '2020'}, { 'key': '10.1016/j.ijantimicag.2020.106248_bib0004', 'article-title': 'Polarization and public health: partisan differences in social ' 'distancing during the coronavirus pandemic. Working Paper 26946', 'author': 'Allcott', 'year': '2020', 'journal-title': 'National Bureau of Economic Research'}, { 'key': '10.1016/j.ijantimicag.2020.106248_bib0005', 'doi-asserted-by': 'crossref', 'DOI': '10.1088/1478-3975/ab9bf5', 'article-title': 'The COVID-19 pandemic: growth patterns, power law scaling, and ' 'saturation', 'volume': '17', 'author': 'Singer', 'year': '2020', 'journal-title': 'Phys Biol'}, { 'key': '10.1016/j.ijantimicag.2020.106248_bib0006', 'doi-asserted-by': 'crossref', 'first-page': '14', 'DOI': '10.1126/science.368.6486.14', 'article-title': 'Vaccine designers take first shots at COVID-19', 'volume': '368', 'author': 'Cohen', 'year': '2020', 'journal-title': 'Science'}, { 'key': '10.1016/j.ijantimicag.2020.106248_bib0007', 'doi-asserted-by': 'crossref', 'first-page': '170', 'DOI': '10.1016/j.jacbts.2016.03.002', 'article-title': 'Drugs, devices, and the FDA: Part 1: an overview of approval processes ' 'for drugs', 'volume': '1', 'year': '2016', 'journal-title': 'JACC Basic Transl Sci'}, { 'key': '10.1016/j.ijantimicag.2020.106248_bib0008', 'doi-asserted-by': 'crossref', 'first-page': '14', 'DOI': '10.1038/s41421-020-0153-3', 'article-title': 'Network-based drug repurposing for novel coronavirus ' '2019-nCoV/SARS-CoV-2', 'volume': '6', 'author': 'Zhou', 'year': '2020', 'journal-title': 'Cell Discov'}, { 'key': '10.1016/j.ijantimicag.2020.106248_bib0009', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.ijantimicag.2020.105932', 'article-title': 'Chloroquine and hydroxychloroquine as available weapons to fight ' 'COVID-19', 'volume': '55', 'author': 'Colson', 'year': '2020', 'journal-title': 'Int J Antimicrob Agents'}, { 'key': '10.1016/j.ijantimicag.2020.106248_bib0010', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.tmaid.2020.101615', 'article-title': 'Remdesivir as a possible therapeutic option for the COVID-19', 'volume': '34', 'author': 'Al-Tawfiq', 'year': '2020', 'journal-title': 'Travel Med Infect Dis'}, { 'key': '10.1016/j.ijantimicag.2020.106248_bib0011', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.antiviral.2020.104787', 'article-title': 'The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 ' 'in vitro', 'volume': '178', 'author': 'Caly', 'year': '2020', 'journal-title': 'Antiviral Res'}, { 'key': '10.1016/j.ijantimicag.2020.106248_bib0012', 'doi-asserted-by': 'crossref', 'first-page': '199', 'DOI': '10.1046/j.1472-8206.2003.00170.x', 'article-title': 'Ivermectin and filariasis', 'volume': '17', 'author': 'Richard-Lenoble', 'year': '2003', 'journal-title': 'Fundam Clin Pharmacol'}, { 'key': '10.1016/j.ijantimicag.2020.106248_bib0013', 'doi-asserted-by': 'crossref', 'first-page': '133', 'DOI': '10.1056/NEJM198507183130301', 'article-title': 'Comparison of ivermectin and diethylcarbamazine in the treatment of ' 'onchocerciasis', 'volume': '313', 'author': 'Greene', 'year': '1985', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.ijantimicag.2020.106248_bib0014', 'doi-asserted-by': 'crossref', 'DOI': '10.2139/ssrn.3636557', 'article-title': 'Ivermectin for COVID-19 treatment: clinical response at quasi-threshold ' 'doses via hypothesized alleviation of CD147-mediated vascular occlusion', 'author': 'Scheim', 'year': '2020', 'journal-title': 'SSRN'}, { 'key': '10.1016/j.ijantimicag.2020.106248_bib0015', 'doi-asserted-by': 'crossref', 'DOI': '10.2139/ssrn.3631261', 'article-title': 'ICON (Ivermectin in COvid Nineteen) Study: use of ivermectin is ' 'associated with lower mortality in hospitalized patients with COVID-19', 'author': 'Rajter', 'year': '2020', 'journal-title': 'SSRN'}, { 'key': '10.1016/j.ijantimicag.2020.106248_bib0016', 'doi-asserted-by': 'crossref', 'first-page': '593', 'DOI': '10.1038/s41429-020-0336-z', 'article-title': 'a systematic review from antiviral effects to COVID-19 complementary ' 'regimen', 'volume': '73', 'author': 'Heidary', 'year': '2020', 'journal-title': 'J Antibiot (Tokyo)'}, { 'key': '10.1016/j.ijantimicag.2020.106248_bib0017', 'doi-asserted-by': 'crossref', 'DOI': '10.1371/journal.pntd.0006020', 'article-title': 'Safety and pharmacokinetic profile of fixed-dose ivermectin with an ' 'innovative 18mg tablet in healthy adult volunteers', 'volume': '12', 'author': 'Muñoz', 'year': '2018', 'journal-title': 'PLoS Negl Trop Dis'}, { 'key': '10.1016/j.ijantimicag.2020.106248_bib0018', 'series-title': 'PCT Databank', 'year': '2020'}, { 'key': '10.1016/j.ijantimicag.2020.106248_bib0019', 'doi-asserted-by': 'crossref', 'first-page': '762', 'DOI': '10.1002/cpt.1889', 'article-title': 'The approved dose of ivermectin alone is not the ideal dose for the ' 'treatment of COVID-19', 'volume': '108', 'author': 'Schmith', 'year': '2020', 'journal-title': 'Clin Pharmacol Ther'}, { 'key': '10.1016/j.ijantimicag.2020.106248_bib0020', 'series-title': 'Ivermectin and abamectin', 'first-page': '113', 'article-title': 'Pharmacokinetics of ivermectin in animals and humans', 'author': 'Fink', 'year': '1989'}, { 'key': '10.1016/j.ijantimicag.2020.106248_bib0021', 'series-title': 'COVID-19 and ivermectin intended for animals', 'year': '2020'}], 'container-title': 'International Journal of Antimicrobial Agents', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S0924857920304684?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S0924857920304684?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2021, 3, 8]], 'date-time': '2021-03-08T09:41:34Z', 'timestamp': 1615196494000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S0924857920304684'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 1]]}, 'references-count': 21, 'journal-issue': {'issue': '1', 'published-print': {'date-parts': [[2021, 1]]}}, 'alternative-id': ['S0924857920304684'], 'URL': 'http://dx.doi.org/10.1016/j.ijantimicag.2020.106248', 'relation': {}, 'ISSN': ['0924-8579'], 'subject': ['Pharmacology (medical)', 'Infectious Diseases', 'Microbiology (medical)', 'General Medicine'], 'container-title-short': 'International Journal of Antimicrobial Agents', 'published': {'date-parts': [[2021, 1]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'A COVID-19 prophylaxis? Lower incidence associated with prophylactic ' 'administration of ivermectin', 'name': 'articletitle', 'label': 'Article Title'}, { 'value': 'International Journal of Antimicrobial Agents', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.ijantimicag.2020.106248', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. ' 'All rights reserved.', 'name': 'copyright', 'label': 'Copyright'}], 'article-number': '106248'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit